ArticleDigital health
Artificial intelligence-based prediction of metabolic dysfunction-associated steatotic liver disease (MASLD) and liver fibrosis in patients with obstructive sleep apnea: An innovative approach.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obstructive sleep apnea (OSA) is strongly associated with metabolic dysfunction and may contribute to the development of hepatic disorders such as metabolic dysfunction-associated steatotic liver disease (MASLD) and liver fibrosis. Early identification of hepatic involvement in OSA is important for preventing long-term complications. This study aimed to develop and compare artificial intelligence (AI)-based models using non-invasive clinical parameters to predict steatosis, MASLD, and liver fibrosis in patients with OSA. Methods: This prospective study included patients diagnosed with OSA based on polysomnography (PSG). Hepatic steatosis and fibrosis were assessed non-invasively using the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) obtained by FibroScan. A total of 700 patients were screened, and 517 patients who met the inclusion criteria were analyzed, including 42 demographic, anthropometric, laboratory, and sleep-related variables. A total of 42 variables were recorded, comprising 37 candidate predictors and 4 target outcomes. Following feature selection, 11 of the 37 candidates were retained for model training. Four supervised machine learning algorithms-logistic regression, support vector machine, random forest, and artificial neural network were trained to predict steatosis, MASLD, and liver fibrosis. Model performance was evaluated by accuracy, F1-score, and area under the ROC curve. Feature importance analysis identified the most influential predictors. Results: Among the four models, the Random Forest algorithm achieved the best performance, with an accuracy of 96% for binary classification; in an exploratory five-class analysis, overall accuracy reached 92%, although predominantly driven by the majority F0 class. The most influential predictors were apnea-hypopnea index (AHI), minimum oxygen saturation (minSpO Conclusion: AI-based models, particularly Random Forest, demonstrated high predictive performance in predicting MASLD and liver fibrosis in OSA patients. These models may support detection and risk stratification of hepatic involvement in sleep-disordered breathing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.